#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=To provide for a repeatable and safe therapy, it is important to provide sufficient power to reach these therapeutic levels and maintain these temperatures for typically about 60 minutes.
1-1	0-2	To	_	_	
1-2	3-10	provide	_	_	
1-3	11-14	for	_	_	
1-4	15-16	a	_	_	
1-5	17-27	repeatable	_	_	
1-6	28-31	and	_	_	
1-7	32-36	safe	_	_	
1-8	37-44	therapy	_	_	
1-9	44-45	,	_	_	
1-10	46-48	it	_	_	
1-11	49-51	is	_	_	
1-12	52-61	important	_	_	
1-13	62-64	to	_	_	
1-14	65-72	provide	_	_	
1-15	73-83	sufficient	_	_	
1-16	84-89	power	_	_	
1-17	90-92	to	_	_	
1-18	93-98	reach	_	_	
1-19	99-104	these	_	_	
1-20	105-116	therapeutic	_	_	
1-21	117-123	levels	_	_	
1-22	124-127	and	_	_	
1-23	128-136	maintain	_	_	
1-24	137-142	these	_	_	
1-25	143-155	temperatures	_	_	
1-26	156-159	for	_	_	
1-27	160-169	typically	_	_	
1-28	170-175	about	_	_	
1-29	176-178	60	_	_	
1-30	179-186	minutes	_	_	
1-31	186-187	.	_	_	

#Text=Higher temperatures would enable shorter times, but patient pain may prevent temperatures in excess of about 48.degree.
2-1	188-194	Higher	_	_	
2-2	195-207	temperatures	_	_	
2-3	208-213	would	_	_	
2-4	214-220	enable	_	_	
2-5	221-228	shorter	_	_	
2-6	229-234	times	_	_	
2-7	234-235	,	_	_	
2-8	236-239	but	_	_	
2-9	240-247	patient	_	_	
2-10	248-252	pain	_	_	
2-11	253-256	may	_	_	
2-12	257-264	prevent	_	_	
2-13	265-277	temperatures	_	_	
2-14	278-280	in	_	_	
2-15	281-287	excess	_	_	
2-16	288-290	of	_	_	
2-17	291-296	about	_	_	
2-18	297-299	48	_	_	
2-19	299-300	.	_	_	
2-20	300-306	degree	_	_	
2-21	306-307	.	_	_	

#Text=C.
3-1	308-309	C	_	_	
3-2	309-310	.	_	_	

#Text=It is possible to incorporate temperature sensors in the applicator to attempt to estimate tissue temperature, but this would also require monitoring to the radiated power and require performing occasional tissue cool-down measurements to estimate the effect of blood flow, tissue thermal conduction, and bolus cooling effects.
4-1	311-313	It	_	_	
4-2	314-316	is	_	_	
4-3	317-325	possible	_	_	
4-4	326-328	to	_	_	
4-5	329-340	incorporate	_	_	
4-6	341-352	temperature	_	_	
4-7	353-360	sensors	_	_	
4-8	361-363	in	_	_	
4-9	364-367	the	_	_	
4-10	368-378	applicator	_	_	
4-11	379-381	to	_	_	
4-12	382-389	attempt	_	_	
4-13	390-392	to	_	_	
4-14	393-401	estimate	_	_	
4-15	402-408	tissue	_	_	
4-16	409-420	temperature	_	_	
4-17	420-421	,	_	_	
4-18	422-425	but	_	_	
4-19	426-430	this	_	_	
4-20	431-436	would	_	_	
4-21	437-441	also	_	_	
4-22	442-449	require	_	_	
4-23	450-460	monitoring	_	_	
4-24	461-463	to	_	_	
4-25	464-467	the	_	_	
4-26	468-476	radiated	_	_	
4-27	477-482	power	_	_	
4-28	483-486	and	_	_	
4-29	487-494	require	_	_	
4-30	495-505	performing	_	_	
4-31	506-516	occasional	_	_	
4-32	517-523	tissue	_	_	
4-33	524-533	cool-down	_	_	
4-34	534-546	measurements	_	_	
4-35	547-549	to	_	_	
4-36	550-558	estimate	_	_	
4-37	559-562	the	_	_	
4-38	563-569	effect	_	_	
4-39	570-572	of	_	_	
4-40	573-578	blood	_	_	
4-41	579-583	flow	_	_	
4-42	583-584	,	_	_	
4-43	585-591	tissue	_	_	
4-44	592-599	thermal	_	_	
4-45	600-610	conduction	_	_	
4-46	610-611	,	_	_	
4-47	612-615	and	_	_	
4-48	616-621	bolus	_	_	
4-49	622-629	cooling	_	_	
4-50	630-637	effects	_	_	
4-51	637-638	.	_	_	

#Text=This is not expected to be as reliable in all patients as compared with a direct temperature measurement.
5-1	639-643	This	_	_	
5-2	644-646	is	_	_	
5-3	647-650	not	_	_	
5-4	651-659	expected	_	_	
5-5	660-662	to	_	_	
5-6	663-665	be	_	_	
5-7	666-668	as	_	_	
5-8	669-677	reliable	_	_	
5-9	678-680	in	_	_	
5-10	681-684	all	_	_	
5-11	685-693	patients	_	_	
5-12	694-696	as	_	_	
5-13	697-705	compared	_	_	
5-14	706-710	with	_	_	
5-15	711-712	a	_	_	
5-16	713-719	direct	_	_	
5-17	720-731	temperature	_	_	
5-18	732-743	measurement	_	_	
5-19	743-744	.	_	_	

#Text=The preferred method to measure the prostate tissue temperature is by using the heating applicator in a receive mode to direct the thermal noise in the heated prostate region into a microwave or US radiometer.
6-1	745-748	The	_	_	
6-2	749-758	preferred	_	_	
6-3	759-765	method	_	_	
6-4	766-768	to	_	_	
6-5	769-776	measure	_	_	
6-6	777-780	the	_	_	
6-7	781-789	prostate	_	_	
6-8	790-796	tissue	_	_	
6-9	797-808	temperature	_	_	
6-10	809-811	is	_	_	
6-11	812-814	by	_	_	
6-12	815-820	using	_	_	
6-13	821-824	the	_	_	
6-14	825-832	heating	_	_	
6-15	833-843	applicator	_	_	
6-16	844-846	in	_	_	
6-17	847-848	a	_	_	
6-18	849-856	receive	_	_	
6-19	857-861	mode	_	_	
6-20	862-864	to	_	_	
6-21	865-871	direct	_	_	
6-22	872-875	the	_	_	
6-23	876-883	thermal	_	_	
6-24	884-889	noise	_	_	
6-25	890-892	in	_	_	
6-26	893-896	the	_	_	
6-27	897-903	heated	_	_	
6-28	904-912	prostate	_	_	
6-29	913-919	region	_	_	
6-30	920-924	into	_	_	
6-31	925-926	a	_	_	
6-32	927-936	microwave	_	_	
6-33	937-939	or	_	_	
6-34	940-942	US	_	_	
6-35	943-953	radiometer	_	_	
6-36	953-954	.	_	_	

#Text=The temperature measurements of the radiometer provide a measurement which is directly related to the temperature within the prostate tissue volume corresponding to the heating volume.
7-1	955-958	The	_	_	
7-2	959-970	temperature	_	_	
7-3	971-983	measurements	_	_	
7-4	984-986	of	_	_	
7-5	987-990	the	_	_	
7-6	991-1001	radiometer	_	_	
7-7	1002-1009	provide	_	_	
7-8	1010-1011	a	_	_	
7-9	1012-1023	measurement	_	_	
7-10	1024-1029	which	_	_	
7-11	1030-1032	is	_	_	
7-12	1033-1041	directly	_	_	
7-13	1042-1049	related	_	_	
7-14	1050-1052	to	_	_	
7-15	1053-1056	the	_	_	
7-16	1057-1068	temperature	_	_	
7-17	1069-1075	within	_	_	
7-18	1076-1079	the	_	_	
7-19	1080-1088	prostate	_	_	
7-20	1089-1095	tissue	_	_	
7-21	1096-1102	volume	_	_	
7-22	1103-1116	corresponding	_	_	
7-23	1117-1119	to	_	_	
7-24	1120-1123	the	_	_	
7-25	1124-1131	heating	_	_	
7-26	1132-1138	volume	_	_	
7-27	1138-1139	.	_	_	

#Text=This measurement is comprised of adding the temperature signals from the various tissue cells within the applicator's heating field.
8-1	1140-1144	This	_	_	
8-2	1145-1156	measurement	_	_	
8-3	1157-1159	is	_	_	
8-4	1160-1169	comprised	_	_	
8-5	1170-1172	of	_	_	
8-6	1173-1179	adding	_	_	
8-7	1180-1183	the	_	_	
8-8	1184-1195	temperature	_	_	
8-9	1196-1203	signals	_	_	
8-10	1204-1208	from	_	_	
8-11	1209-1212	the	_	_	
8-12	1213-1220	various	_	_	
8-13	1221-1227	tissue	_	_	
8-14	1228-1233	cells	_	_	
8-15	1234-1240	within	_	_	
8-16	1241-1244	the	_	_	
8-17	1245-1257	applicator's	_	_	
8-18	1258-1265	heating	_	_	
8-19	1266-1271	field	_	_	
8-20	1271-1272	.	_	_	

#Text=Therefore, this measurement is like having thousands of individual temperature points which are measured and then added together to provide an indication of the average temperatures within the heated region.
9-1	1273-1282	Therefore	*[1]	10-1[2_1]	
9-2	1282-1283	,	*[1]	_	
9-3	1284-1288	this	*[1]	_	
9-4	1289-1300	measurement	*[1]	_	
9-5	1301-1303	is	*[1]	_	
9-6	1304-1308	like	*[1]	_	
9-7	1309-1315	having	*[1]	_	
9-8	1316-1325	thousands	*[1]	_	
9-9	1326-1328	of	*[1]	_	
9-10	1329-1339	individual	*[1]	_	
9-11	1340-1351	temperature	*[1]	_	
9-12	1352-1358	points	*[1]	_	
9-13	1359-1364	which	*[1]	_	
9-14	1365-1368	are	*[1]	_	
9-15	1369-1377	measured	*[1]	_	
9-16	1378-1381	and	*[1]	_	
9-17	1382-1386	then	*[1]	_	
9-18	1387-1392	added	*[1]	_	
9-19	1393-1401	together	*[1]	_	
9-20	1402-1404	to	*[1]	_	
9-21	1405-1412	provide	*[1]	_	
9-22	1413-1415	an	*[1]	_	
9-23	1416-1426	indication	*[1]	_	
9-24	1427-1429	of	*[1]	_	
9-25	1430-1433	the	*[1]	_	
9-26	1434-1441	average	*[1]	_	
9-27	1442-1454	temperatures	*[1]	_	
9-28	1455-1461	within	*[1]	_	
9-29	1462-1465	the	*[1]	_	
9-30	1466-1472	heated	*[1]	_	
9-31	1473-1479	region	*[1]	_	
9-32	1479-1480	.	*[1]	_	

#Text=This method does not measure the maximum or the minimum temperature in the heated tissue, but provides an accurate measure of the average tissue temperature within the treatment zone.
10-1	1481-1485	This	*[2]	_	
10-2	1486-1492	method	*[2]	_	
10-3	1493-1497	does	_	_	
10-4	1498-1501	not	_	_	
10-5	1502-1509	measure	_	_	
10-6	1510-1513	the	_	_	
10-7	1514-1521	maximum	_	_	
10-8	1522-1524	or	_	_	
10-9	1525-1528	the	_	_	
10-10	1529-1536	minimum	_	_	
10-11	1537-1548	temperature	_	_	
10-12	1549-1551	in	_	_	
10-13	1552-1555	the	_	_	
10-14	1556-1562	heated	_	_	
10-15	1563-1569	tissue	_	_	
10-16	1569-1570	,	_	_	
10-17	1571-1574	but	_	_	
10-18	1575-1583	provides	_	_	
10-19	1584-1586	an	_	_	
10-20	1587-1595	accurate	_	_	
10-21	1596-1603	measure	_	_	
10-22	1604-1606	of	_	_	
10-23	1607-1610	the	_	_	
10-24	1611-1618	average	_	_	
10-25	1619-1625	tissue	_	_	
10-26	1626-1637	temperature	_	_	
10-27	1638-1644	within	_	_	
10-28	1645-1648	the	_	_	
10-29	1649-1658	treatment	_	_	
10-30	1659-1663	zone	_	_	
10-31	1663-1664	.	_	_	

#Text=This new method enables the treatment of benign prostate disease to be efficiently treated with hyperthermia, where the tissue being treated is the same tissue which would have been surgically removed by a TURP.
11-1	1665-1669	This	_	_	
11-2	1670-1673	new	_	_	
11-3	1674-1680	method	_	_	
11-4	1681-1688	enables	_	_	
11-5	1689-1692	the	_	_	
11-6	1693-1702	treatment	_	_	
11-7	1703-1705	of	_	_	
11-8	1706-1712	benign	_	_	
11-9	1713-1721	prostate	_	_	
11-10	1722-1729	disease	_	_	
11-11	1730-1732	to	_	_	
11-12	1733-1735	be	_	_	
11-13	1736-1747	efficiently	_	_	
11-14	1748-1755	treated	_	_	
11-15	1756-1760	with	_	_	
11-16	1761-1773	hyperthermia	_	_	
11-17	1773-1774	,	_	_	
11-18	1775-1780	where	_	_	
11-19	1781-1784	the	_	_	
11-20	1785-1791	tissue	_	_	
11-21	1792-1797	being	_	_	
11-22	1798-1805	treated	_	_	
11-23	1806-1808	is	_	_	
11-24	1809-1812	the	_	_	
11-25	1813-1817	same	_	_	
11-26	1818-1824	tissue	_	_	
11-27	1825-1830	which	_	_	
11-28	1831-1836	would	_	_	
11-29	1837-1841	have	_	_	
11-30	1842-1846	been	_	_	
11-31	1847-1857	surgically	_	_	
11-32	1858-1865	removed	_	_	
11-33	1866-1868	by	_	_	
11-34	1869-1870	a	_	_	
11-35	1871-1875	TURP	_	_	
11-36	1875-1876	.	_	_	

#Text=In many patients there are severe side effects by the TURP procedure such as incontinence, retrograde ejaculation, impotency, and death.
12-1	1877-1879	In	_	_	
12-2	1880-1884	many	_	_	
12-3	1885-1893	patients	_	_	
12-4	1894-1899	there	_	_	
12-5	1900-1903	are	_	_	
12-6	1904-1910	severe	_	_	
12-7	1911-1915	side	_	_	
12-8	1916-1923	effects	_	_	
12-9	1924-1926	by	_	_	
12-10	1927-1930	the	_	_	
12-11	1931-1935	TURP	_	_	
12-12	1936-1945	procedure	_	_	
12-13	1946-1950	such	_	_	
12-14	1951-1953	as	_	_	
12-15	1954-1966	incontinence	_	_	
12-16	1966-1967	,	_	_	
12-17	1968-1978	retrograde	_	_	
12-18	1979-1990	ejaculation	_	_	
12-19	1990-1991	,	_	_	
12-20	1992-2001	impotency	_	_	
12-21	2001-2002	,	_	_	
12-22	2003-2006	and	_	_	
12-23	2007-2012	death	_	_	
12-24	2012-2013	.	_	_	

#Text=It is estimated that between 0.3 to 3% of the patients receiving the TURP surgical procedure die from either the procedure or by other factors related to the procedure.
13-1	2014-2016	It	_	_	
13-2	2017-2019	is	_	_	
13-3	2020-2029	estimated	_	_	
13-4	2030-2034	that	_	_	
13-5	2035-2042	between	_	_	
13-6	2043-2046	0.3	_	_	
13-7	2047-2049	to	_	_	
13-8	2050-2052	3%	_	_	
13-9	2053-2055	of	_	_	
13-10	2056-2059	the	_	_	
13-11	2060-2068	patients	_	_	
13-12	2069-2078	receiving	_	_	
13-13	2079-2082	the	_	_	
13-14	2083-2087	TURP	_	_	
13-15	2088-2096	surgical	_	_	
13-16	2097-2106	procedure	_	_	
13-17	2107-2110	die	_	_	
13-18	2111-2115	from	_	_	
13-19	2116-2122	either	_	_	
13-20	2123-2126	the	_	_	
13-21	2127-2136	procedure	_	_	
13-22	2137-2139	or	_	_	
13-23	2140-2142	by	_	_	
13-24	2143-2148	other	_	_	
13-25	2149-2156	factors	_	_	
13-26	2157-2164	related	_	_	
13-27	2165-2167	to	_	_	
13-28	2168-2171	the	_	_	
13-29	2172-2181	procedure	_	_	
13-30	2181-2182	.	_	_	

#Text=Many patients are poor surgical risks due to their age and poor health.
14-1	2183-2187	Many	_	_	
14-2	2188-2196	patients	_	_	
14-3	2197-2200	are	_	_	
14-4	2201-2205	poor	_	_	
14-5	2206-2214	surgical	_	_	
14-6	2215-2220	risks	_	_	
14-7	2221-2224	due	_	_	
14-8	2225-2227	to	_	_	
14-9	2228-2233	their	_	_	
14-10	2234-2237	age	_	_	
14-11	2238-2241	and	_	_	
14-12	2242-2246	poor	_	_	
14-13	2247-2253	health	_	_	
14-14	2253-2254	.	_	_	

#Text=The use of hyperthermia treatments as described herein, represent a non-surgical alternative therapy for the benign prostate disease.
15-1	2255-2258	The	_	_	
15-2	2259-2262	use	_	_	
15-3	2263-2265	of	_	_	
15-4	2266-2278	hyperthermia	_	_	
15-5	2279-2289	treatments	_	_	
15-6	2290-2292	as	_	_	
15-7	2293-2302	described	_	_	
15-8	2303-2309	herein	_	_	
15-9	2309-2310	,	_	_	
15-10	2311-2320	represent	_	_	
15-11	2321-2322	a	_	_	
15-12	2323-2335	non-surgical	_	_	
15-13	2336-2347	alternative	_	_	
15-14	2348-2355	therapy	_	_	
15-15	2356-2359	for	_	_	
15-16	2360-2363	the	_	_	
15-17	2364-2370	benign	_	_	
15-18	2371-2379	prostate	_	_	
15-19	2380-2387	disease	_	_	
15-20	2387-2388	.	_	_	

#Text=The optimal combined utilization of the urethra inserted radiating energy microwave source, the circulation cooling fluid in the urethra, the positioning and urine drainage system of the Foley catheter, and the microwave radiometry provides a very practical method to treat benign prostate disease.
16-1	2389-2392	The	_	_	
16-2	2393-2400	optimal	_	_	
16-3	2401-2409	combined	_	_	
16-4	2410-2421	utilization	_	_	
16-5	2422-2424	of	_	_	
16-6	2425-2428	the	_	_	
16-7	2429-2436	urethra	_	_	
16-8	2437-2445	inserted	_	_	
16-9	2446-2455	radiating	_	_	
16-10	2456-2462	energy	_	_	
16-11	2463-2472	microwave	_	_	
16-12	2473-2479	source	_	_	
16-13	2479-2480	,	_	_	
16-14	2481-2484	the	_	_	
16-15	2485-2496	circulation	_	_	
16-16	2497-2504	cooling	_	_	
16-17	2505-2510	fluid	_	_	
16-18	2511-2513	in	_	_	
16-19	2514-2517	the	_	_	
16-20	2518-2525	urethra	_	_	
16-21	2525-2526	,	_	_	
16-22	2527-2530	the	_	_	
16-23	2531-2542	positioning	_	_	
16-24	2543-2546	and	_	_	
16-25	2547-2552	urine	_	_	
16-26	2553-2561	drainage	_	_	
16-27	2562-2568	system	_	_	
16-28	2569-2571	of	_	_	
16-29	2572-2575	the	_	_	
16-30	2576-2581	Foley	_	_	
16-31	2582-2590	catheter	_	_	
16-32	2590-2591	,	_	_	
16-33	2592-2595	and	_	_	
16-34	2596-2599	the	_	_	
16-35	2600-2609	microwave	_	_	
16-36	2610-2620	radiometry	_	_	
16-37	2621-2629	provides	_	_	
16-38	2630-2631	a	_	_	
16-39	2632-2636	very	_	_	
16-40	2637-2646	practical	_	_	
16-41	2647-2653	method	_	_	
16-42	2654-2656	to	_	_	
16-43	2657-2662	treat	_	_	
16-44	2663-2669	benign	_	_	
16-45	2670-2678	prostate	_	_	
16-46	2679-2686	disease	_	_	
16-47	2686-2687	.	_	_	

#Text=It is also feasible that this method will be suitable for the treatment of malignant prostate disease.
17-1	2688-2690	It	_	_	
17-2	2691-2693	is	_	_	
17-3	2694-2698	also	_	_	
17-4	2699-2707	feasible	_	_	
17-5	2708-2712	that	_	_	
17-6	2713-2717	this	_	_	
17-7	2718-2724	method	_	_	
17-8	2725-2729	will	_	_	
17-9	2730-2732	be	_	_	
17-10	2733-2741	suitable	_	_	
17-11	2742-2745	for	_	_	
17-12	2746-2749	the	_	_	
17-13	2750-2759	treatment	_	_	
17-14	2760-2762	of	_	_	
17-15	2763-2772	malignant	_	_	
17-16	2773-2781	prostate	_	_	
17-17	2782-2789	disease	_	_	
17-18	2789-2790	.	_	_	

#Text=The malignant prostate disease normally involves a larger size mass requiring treatment than is possible with the urethra inserted applicators.
18-1	2791-2794	The	_	_	
18-2	2795-2804	malignant	_	_	
18-3	2805-2813	prostate	_	_	
18-4	2814-2821	disease	_	_	
18-5	2822-2830	normally	_	_	
18-6	2831-2839	involves	_	_	
18-7	2840-2841	a	_	_	
18-8	2842-2848	larger	_	_	
18-9	2849-2853	size	_	_	
18-10	2854-2858	mass	_	_	
18-11	2859-2868	requiring	_	_	
18-12	2869-2878	treatment	_	_	
18-13	2879-2883	than	_	_	
18-14	2884-2886	is	_	_	
18-15	2887-2895	possible	_	_	
18-16	2896-2900	with	_	_	
18-17	2901-2904	the	_	_	
18-18	2905-2912	urethra	_	_	
18-19	2913-2921	inserted	_	_	
18-20	2922-2933	applicators	_	_	
18-21	2933-2934	.	_	_	

#Text=However, the increased treatment volume provided by this new method may enable some malignant prostate tumors to be effectively treated as long as the tumor resides within the therapeutic heating area which extends to about 0.8 cm away from the inserted applicator wall.
19-1	2935-2942	However	_	_	
19-2	2942-2943	,	_	_	
19-3	2944-2947	the	_	_	
19-4	2948-2957	increased	_	_	
19-5	2958-2967	treatment	_	_	
19-6	2968-2974	volume	_	_	
19-7	2975-2983	provided	_	_	
19-8	2984-2986	by	_	_	
19-9	2987-2991	this	_	_	
19-10	2992-2995	new	_	_	
19-11	2996-3002	method	_	_	
19-12	3003-3006	may	_	_	
19-13	3007-3013	enable	_	_	
19-14	3014-3018	some	_	_	
19-15	3019-3028	malignant	_	_	
19-16	3029-3037	prostate	_	_	
19-17	3038-3044	tumors	_	_	
19-18	3045-3047	to	_	_	
19-19	3048-3050	be	_	_	
19-20	3051-3062	effectively	_	_	
19-21	3063-3070	treated	_	_	
19-22	3071-3073	as	_	_	
19-23	3074-3078	long	_	_	
19-24	3079-3081	as	_	_	
19-25	3082-3085	the	_	_	
19-26	3086-3091	tumor	_	_	
19-27	3092-3099	resides	_	_	
19-28	3100-3106	within	_	_	
19-29	3107-3110	the	_	_	
19-30	3111-3122	therapeutic	_	_	
19-31	3123-3130	heating	_	_	
19-32	3131-3135	area	_	_	
19-33	3136-3141	which	_	_	
19-34	3142-3149	extends	_	_	
19-35	3150-3152	to	_	_	
19-36	3153-3158	about	_	_	
19-37	3159-3162	0.8	_	_	
19-38	3163-3165	cm	_	_	
19-39	3166-3170	away	_	_	
19-40	3171-3175	from	_	_	
19-41	3176-3179	the	_	_	
19-42	3180-3188	inserted	_	_	
19-43	3189-3199	applicator	_	_	
19-44	3200-3204	wall	_	_	
19-45	3204-3205	.	_	_	

#Text=Certainly if the urethral blockage through the prostate is caused by malignant growth, the use of this method to relieve the blockage symptom is also feasible, even though the intent would possibly not be to cure the cancer if the cancerous growth was larger than the heating volume.
20-1	3206-3215	Certainly	_	_	
20-2	3216-3218	if	_	_	
20-3	3219-3222	the	_	_	
20-4	3223-3231	urethral	_	_	
20-5	3232-3240	blockage	_	_	
20-6	3241-3248	through	_	_	
20-7	3249-3252	the	_	_	
20-8	3253-3261	prostate	_	_	
20-9	3262-3264	is	_	_	
20-10	3265-3271	caused	_	_	
20-11	3272-3274	by	_	_	
20-12	3275-3284	malignant	_	_	
20-13	3285-3291	growth	_	_	
20-14	3291-3292	,	_	_	
20-15	3293-3296	the	_	_	
20-16	3297-3300	use	_	_	
20-17	3301-3303	of	_	_	
20-18	3304-3308	this	_	_	
20-19	3309-3315	method	_	_	
20-20	3316-3318	to	_	_	
20-21	3319-3326	relieve	_	_	
20-22	3327-3330	the	_	_	
20-23	3331-3339	blockage	_	_	
20-24	3340-3347	symptom	_	_	
20-25	3348-3350	is	_	_	
20-26	3351-3355	also	_	_	
20-27	3356-3364	feasible	_	_	
20-28	3364-3365	,	_	_	
20-29	3366-3370	even	_	_	
20-30	3371-3377	though	_	_	
20-31	3378-3381	the	_	_	
20-32	3382-3388	intent	_	_	
20-33	3389-3394	would	_	_	
20-34	3395-3403	possibly	_	_	
20-35	3404-3407	not	_	_	
20-36	3408-3410	be	_	_	
20-37	3411-3413	to	_	_	
20-38	3414-3418	cure	_	_	
20-39	3419-3422	the	_	_	
20-40	3423-3429	cancer	_	_	
20-41	3430-3432	if	_	_	
20-42	3433-3436	the	_	_	
20-43	3437-3446	cancerous	_	_	
20-44	3447-3453	growth	_	_	
20-45	3454-3457	was	_	_	
20-46	3458-3464	larger	_	_	
20-47	3465-3469	than	_	_	
20-48	3470-3473	the	_	_	
20-49	3474-3481	heating	_	_	
20-50	3482-3488	volume	_	_	
20-51	3488-3489	.	_	_	

#Text=The use of ultrasound crystal cylinders is also considered feasible with this method which can operate as both energy transmitters as well as ultrasound radiometric temperature sensors.
21-1	3490-3493	The	_	_	
21-2	3494-3497	use	_	_	
21-3	3498-3500	of	_	_	
21-4	3501-3511	ultrasound	_	_	
21-5	3512-3519	crystal	_	_	
21-6	3520-3529	cylinders	_	_	
21-7	3530-3532	is	_	_	
21-8	3533-3537	also	_	_	
21-9	3538-3548	considered	_	_	
21-10	3549-3557	feasible	_	_	
21-11	3558-3562	with	_	_	
21-12	3563-3567	this	_	_	
21-13	3568-3574	method	_	_	
21-14	3575-3580	which	_	_	
21-15	3581-3584	can	_	_	
21-16	3585-3592	operate	_	_	
21-17	3593-3595	as	_	_	
21-18	3596-3600	both	_	_	
21-19	3601-3607	energy	_	_	
21-20	3608-3620	transmitters	_	_	
21-21	3621-3623	as	_	_	
21-22	3624-3628	well	_	_	
21-23	3629-3631	as	_	_	
21-24	3632-3642	ultrasound	_	_	
21-25	3643-3654	radiometric	_	_	
21-26	3655-3666	temperature	_	_	
21-27	3667-3674	sensors	_	_	
21-28	3674-3675	.	_	_	

#Text=In this form, the ultrasonic thermal energy radiated by the tissue within the ultrasound applicator's heating zone will be detected by the ultrasound radiometer.
22-1	3676-3678	In	_	_	
22-2	3679-3683	this	_	_	
22-3	3684-3688	form	_	_	
22-4	3688-3689	,	_	_	
22-5	3690-3693	the	_	_	
22-6	3694-3704	ultrasonic	_	_	
22-7	3705-3712	thermal	_	_	
22-8	3713-3719	energy	_	_	
22-9	3720-3728	radiated	_	_	
22-10	3729-3731	by	_	_	
22-11	3732-3735	the	_	_	
22-12	3736-3742	tissue	_	_	
22-13	3743-3749	within	_	_	
22-14	3750-3753	the	_	_	
22-15	3754-3764	ultrasound	_	_	
22-16	3765-3777	applicator's	_	_	
22-17	3778-3785	heating	_	_	
22-18	3786-3790	zone	_	_	
22-19	3791-3795	will	_	_	
22-20	3796-3798	be	_	_	
22-21	3799-3807	detected	_	_	
22-22	3808-3810	by	_	_	
22-23	3811-3814	the	_	_	
22-24	3815-3825	ultrasound	_	_	
22-25	3826-3836	radiometer	_	_	
22-26	3836-3837	.	_	_	

#Text=This would therefore be equivalent to the microwave urethral inserted applicator, but would operate at ultrasound frequencies.
23-1	3838-3842	This	_	_	
23-2	3843-3848	would	_	_	
23-3	3849-3858	therefore	_	_	
23-4	3859-3861	be	_	_	
23-5	3862-3872	equivalent	_	_	
23-6	3873-3875	to	_	_	
23-7	3876-3879	the	_	_	
23-8	3880-3889	microwave	_	_	
23-9	3890-3898	urethral	_	_	
23-10	3899-3907	inserted	_	_	
23-11	3908-3918	applicator	_	_	
23-12	3918-3919	,	_	_	
23-13	3920-3923	but	_	_	
23-14	3924-3929	would	_	_	
23-15	3930-3937	operate	_	_	
23-16	3938-3940	at	_	_	
23-17	3941-3951	ultrasound	_	_	
23-18	3952-3963	frequencies	_	_	
23-19	3963-3964	.	_	_	

#Text=Various ultrasound cylinders are commonly available such as from The EBL Company of Hartford, Conn.
24-1	3965-3972	Various	_	_	
24-2	3973-3983	ultrasound	_	_	
24-3	3984-3993	cylinders	_	_	
24-4	3994-3997	are	_	_	
24-5	3998-4006	commonly	_	_	
24-6	4007-4016	available	_	_	
24-7	4017-4021	such	_	_	
24-8	4022-4024	as	_	_	
24-9	4025-4029	from	_	_	
24-10	4030-4033	The	_	_	
24-11	4034-4037	EBL	_	_	
24-12	4038-4045	Company	_	_	
24-13	4046-4048	of	_	_	
24-14	4049-4057	Hartford	_	_	
24-15	4057-4058	,	_	_	
24-16	4059-4063	Conn	_	_	
24-17	4063-4064	.	_	_	

#Text=It is preferred that a longitudinal stack of ultrasound crystals be used to enable more flexibility and bending of the inserted crystals.
25-1	4065-4067	It	_	_	
25-2	4068-4070	is	_	_	
25-3	4071-4080	preferred	_	_	
25-4	4081-4085	that	_	_	
25-5	4086-4087	a	_	_	
25-6	4088-4100	longitudinal	_	_	
25-7	4101-4106	stack	_	_	
25-8	4107-4109	of	_	_	
25-9	4110-4120	ultrasound	_	_	
25-10	4121-4129	crystals	_	_	
25-11	4130-4132	be	_	_	
25-12	4133-4137	used	_	_	
25-13	4138-4140	to	_	_	
25-14	4141-4147	enable	_	_	
25-15	4148-4152	more	_	_	
25-16	4153-4164	flexibility	_	_	
25-17	4165-4168	and	_	_	
25-18	4169-4176	bending	_	_	
25-19	4177-4179	of	_	_	
25-20	4180-4183	the	_	_	
25-21	4184-4192	inserted	_	_	
25-22	4193-4201	crystals	_	_	
25-23	4201-4202	.	_	_	

#Text=During radiometry measurements, it is possible that EM noise sources other than the heated tissue, such as fluorescent lights, radio stations, microwave ovens, etc., can interfere with the accurate operation of the EM radiometer.
26-1	4203-4209	During	_	_	
26-2	4210-4220	radiometry	_	_	
26-3	4221-4233	measurements	_	_	
26-4	4233-4234	,	_	_	
26-5	4235-4237	it	_	_	
26-6	4238-4240	is	_	_	
26-7	4241-4249	possible	_	_	
26-8	4250-4254	that	_	_	
26-9	4255-4257	EM	_	_	
26-10	4258-4263	noise	_	_	
26-11	4264-4271	sources	_	_	
26-12	4272-4277	other	_	_	
26-13	4278-4282	than	_	_	
26-14	4283-4286	the	_	_	
26-15	4287-4293	heated	_	_	
26-16	4294-4300	tissue	_	_	
26-17	4300-4301	,	_	_	
26-18	4302-4306	such	_	_	
26-19	4307-4309	as	_	_	
26-20	4310-4321	fluorescent	_	_	
26-21	4322-4328	lights	_	_	
26-22	4328-4329	,	_	_	
26-23	4330-4335	radio	_	_	
26-24	4336-4344	stations	_	_	
26-25	4344-4345	,	_	_	
26-26	4346-4355	microwave	_	_	
26-27	4356-4361	ovens	_	_	
26-28	4361-4362	,	_	_	
26-29	4363-4366	etc	_	_	
26-30	4366-4367	.	_	_	
26-31	4367-4368	,	_	_	
26-32	4369-4372	can	_	_	
26-33	4373-4382	interfere	_	_	
26-34	4383-4387	with	_	_	
26-35	4388-4391	the	_	_	
26-36	4392-4400	accurate	_	_	
26-37	4401-4410	operation	_	_	
26-38	4411-4413	of	_	_	
26-39	4414-4417	the	_	_	
26-40	4418-4420	EM	_	_	
26-41	4421-4431	radiometer	_	_	
26-42	4431-4432	.	_	_	

#Text=It is possible to perform the application of this EM method inside a metallic shielded room to block out many EM sources which would otherwise possibly interfere with the EM radiometry operation.
27-1	4433-4435	It	_	_	
27-2	4436-4438	is	_	_	
27-3	4439-4447	possible	_	_	
27-4	4448-4450	to	_	_	
27-5	4451-4458	perform	_	_	
27-6	4459-4462	the	_	_	
27-7	4463-4474	application	_	_	
27-8	4475-4477	of	_	_	
27-9	4478-4482	this	_	_	
27-10	4483-4485	EM	_	_	
27-11	4486-4492	method	_	_	
27-12	4493-4499	inside	_	_	
27-13	4500-4501	a	_	_	
27-14	4502-4510	metallic	_	_	
27-15	4511-4519	shielded	_	_	
27-16	4520-4524	room	_	_	
27-17	4525-4527	to	_	_	
27-18	4528-4533	block	_	_	
27-19	4534-4537	out	_	_	
27-20	4538-4542	many	_	_	
27-21	4543-4545	EM	_	_	
27-22	4546-4553	sources	_	_	
27-23	4554-4559	which	_	_	
27-24	4560-4565	would	_	_	
27-25	4566-4575	otherwise	_	_	
27-26	4576-4584	possibly	_	_	
27-27	4585-4594	interfere	_	_	
27-28	4595-4599	with	_	_	
27-29	4600-4603	the	_	_	
27-30	4604-4606	EM	_	_	
27-31	4607-4617	radiometry	_	_	
27-32	4618-4627	operation	_	_	
27-33	4627-4628	.	_	_	

#Text=The addition of a shielded room facility to improve the operation of a radiometer is not considered novel, but is well known in the current application of radiometry.
28-1	4629-4632	The	_	_	
28-2	4633-4641	addition	_	_	
28-3	4642-4644	of	_	_	
28-4	4645-4646	a	_	_	
28-5	4647-4655	shielded	_	_	
28-6	4656-4660	room	_	_	
28-7	4661-4669	facility	_	_	
28-8	4670-4672	to	_	_	
28-9	4673-4680	improve	_	_	
28-10	4681-4684	the	_	_	
28-11	4685-4694	operation	_	_	
28-12	4695-4697	of	_	_	
28-13	4698-4699	a	_	_	
28-14	4700-4710	radiometer	_	_	
28-15	4711-4713	is	_	_	
28-16	4714-4717	not	_	_	
28-17	4718-4728	considered	_	_	
28-18	4729-4734	novel	_	_	
28-19	4734-4735	,	_	_	
28-20	4736-4739	but	_	_	
28-21	4740-4742	is	_	_	
28-22	4743-4747	well	_	_	
28-23	4748-4753	known	_	_	
28-24	4754-4756	in	_	_	
28-25	4757-4760	the	_	_	
28-26	4761-4768	current	_	_	
28-27	4769-4780	application	_	_	
28-28	4781-4783	of	_	_	
28-29	4784-4794	radiometry	_	_	
28-30	4794-4795	.	_	_	

#Text=However, where a shielded room is not available, or where other EM sources may be located in the shielded room, it is useful to include an electrically conductive shield or blanket over or around the patient in the treatment area to reduce the effects of these other EM noise sources on the radiometer.
29-1	4796-4803	However	_	_	
29-2	4803-4804	,	_	_	
29-3	4805-4810	where	_	_	
29-4	4811-4812	a	_	_	
29-5	4813-4821	shielded	_	_	
29-6	4822-4826	room	_	_	
29-7	4827-4829	is	_	_	
29-8	4830-4833	not	_	_	
29-9	4834-4843	available	_	_	
29-10	4843-4844	,	_	_	
29-11	4845-4847	or	_	_	
29-12	4848-4853	where	_	_	
29-13	4854-4859	other	_	_	
29-14	4860-4862	EM	_	_	
29-15	4863-4870	sources	_	_	
29-16	4871-4874	may	_	_	
29-17	4875-4877	be	_	_	
29-18	4878-4885	located	_	_	
29-19	4886-4888	in	_	_	
29-20	4889-4892	the	_	_	
29-21	4893-4901	shielded	_	_	
29-22	4902-4906	room	_	_	
29-23	4906-4907	,	_	_	
29-24	4908-4910	it	_	_	
29-25	4911-4913	is	_	_	
29-26	4914-4920	useful	_	_	
29-27	4921-4923	to	_	_	
29-28	4924-4931	include	_	_	
29-29	4932-4934	an	_	_	
29-30	4935-4947	electrically	_	_	
29-31	4948-4958	conductive	_	_	
29-32	4959-4965	shield	_	_	
29-33	4966-4968	or	_	_	
29-34	4969-4976	blanket	_	_	
29-35	4977-4981	over	_	_	
29-36	4982-4984	or	_	_	
29-37	4985-4991	around	_	_	
29-38	4992-4995	the	_	_	
29-39	4996-5003	patient	_	_	
29-40	5004-5006	in	_	_	
29-41	5007-5010	the	_	_	
29-42	5011-5020	treatment	_	_	
29-43	5021-5025	area	_	_	
29-44	5026-5028	to	_	_	
29-45	5029-5035	reduce	_	_	
29-46	5036-5039	the	_	_	
29-47	5040-5047	effects	_	_	
29-48	5048-5050	of	_	_	
29-49	5051-5056	these	_	_	
29-50	5057-5062	other	_	_	
29-51	5063-5065	EM	_	_	
29-52	5066-5071	noise	_	_	
29-53	5072-5079	sources	_	_	
29-54	5080-5082	on	_	_	
29-55	5083-5086	the	_	_	
29-56	5087-5097	radiometer	_	_	
29-57	5097-5098	.	_	_	

#Text=Suitable materials for this shielding blanket are metal screen or mesh, such as that produced by Cleveland Wire Cloth Manufacturing Company of Cleveland, Ohio.
30-1	5099-5107	Suitable	_	_	
30-2	5108-5117	materials	_	_	
30-3	5118-5121	for	_	_	
30-4	5122-5126	this	_	_	
30-5	5127-5136	shielding	_	_	
30-6	5137-5144	blanket	_	_	
30-7	5145-5148	are	_	_	
30-8	5149-5154	metal	_	_	
30-9	5155-5161	screen	_	_	
30-10	5162-5164	or	_	_	
30-11	5165-5169	mesh	_	_	
30-12	5169-5170	,	_	_	
30-13	5171-5175	such	_	_	
30-14	5176-5178	as	_	_	
30-15	5179-5183	that	_	_	
30-16	5184-5192	produced	_	_	
30-17	5193-5195	by	_	_	
30-18	5196-5205	Cleveland	_	_	
30-19	5206-5210	Wire	_	_	
30-20	5211-5216	Cloth	_	_	
30-21	5217-5230	Manufacturing	_	_	
30-22	5231-5238	Company	_	_	
30-23	5239-5241	of	_	_	
30-24	5242-5251	Cleveland	_	_	
30-25	5251-5252	,	_	_	
30-26	5253-5257	Ohio	_	_	
30-27	5257-5258	.	_	_	

#Text=The conductive sheet may be in the form of a metal impregnated paper such as that produced by Zippertubing Company of Los Angeles, Calif., or by International Paper of Tuxedo, N.Y.
31-1	5259-5262	The	_	_	
31-2	5263-5273	conductive	_	_	
31-3	5274-5279	sheet	_	_	
31-4	5280-5283	may	_	_	
31-5	5284-5286	be	_	_	
31-6	5287-5289	in	_	_	
31-7	5290-5293	the	_	_	
31-8	5294-5298	form	_	_	
31-9	5299-5301	of	_	_	
31-10	5302-5303	a	_	_	
31-11	5304-5309	metal	_	_	
31-12	5310-5321	impregnated	_	_	
31-13	5322-5327	paper	_	_	
31-14	5328-5332	such	_	_	
31-15	5333-5335	as	_	_	
31-16	5336-5340	that	_	_	
31-17	5341-5349	produced	_	_	
31-18	5350-5352	by	_	_	
31-19	5353-5365	Zippertubing	_	_	
31-20	5366-5373	Company	_	_	
31-21	5374-5376	of	_	_	
31-22	5377-5380	Los	_	_	
31-23	5381-5388	Angeles	_	_	
31-24	5388-5389	,	_	_	
31-25	5390-5395	Calif	_	_	
31-26	5395-5396	.	_	_	
31-27	5396-5397	,	_	_	
31-28	5398-5400	or	_	_	
31-29	5401-5403	by	_	_	
31-30	5404-5417	International	_	_	
31-31	5418-5423	Paper	_	_	
31-32	5424-5426	of	_	_	
31-33	5427-5433	Tuxedo	_	_	
31-34	5433-5434	,	_	_	
31-35	5435-5438	N.Y	_	_	
31-36	5438-5439	.	_	_	

#Text=The conductive sheet may even be a metal foil sheet which is commonly marketed as aluminum foil.
32-1	5440-5443	The	_	_	
32-2	5444-5454	conductive	_	_	
32-3	5455-5460	sheet	_	_	
32-4	5461-5464	may	_	_	
32-5	5465-5469	even	_	_	
32-6	5470-5472	be	_	_	
32-7	5473-5474	a	_	_	
32-8	5475-5480	metal	_	_	
32-9	5481-5485	foil	_	_	
32-10	5486-5491	sheet	_	_	
32-11	5492-5497	which	_	_	
32-12	5498-5500	is	_	_	
32-13	5501-5509	commonly	_	_	
32-14	5510-5518	marketed	_	_	
32-15	5519-5521	as	_	_	
32-16	5522-5530	aluminum	_	_	
32-17	5531-5535	foil	_	_	
32-18	5535-5536	.	_	_	

#Text=A practical other shielding material is conductive cloth such as that manufactured by Devex S.A. of Denis, Switzerland, or the Hexcel Corporation of Dublin, Calif.
33-1	5537-5538	A	_	_	
33-2	5539-5548	practical	_	_	
33-3	5549-5554	other	_	_	
33-4	5555-5564	shielding	_	_	
33-5	5565-5573	material	_	_	
33-6	5574-5576	is	_	_	
33-7	5577-5587	conductive	_	_	
33-8	5588-5593	cloth	_	_	
33-9	5594-5598	such	_	_	
33-10	5599-5601	as	_	_	
33-11	5602-5606	that	_	_	
33-12	5607-5619	manufactured	_	_	
33-13	5620-5622	by	_	_	
33-14	5623-5628	Devex	_	_	
33-15	5629-5632	S.A	_	_	
33-16	5632-5633	.	_	_	
33-17	5634-5636	of	_	_	
33-18	5637-5642	Denis	_	_	
33-19	5642-5643	,	_	_	
33-20	5644-5655	Switzerland	_	_	
33-21	5655-5656	,	_	_	
33-22	5657-5659	or	_	_	
33-23	5660-5663	the	_	_	
33-24	5664-5670	Hexcel	_	_	
33-25	5671-5682	Corporation	_	_	
33-26	5683-5685	of	_	_	
33-27	5686-5692	Dublin	_	_	
33-28	5692-5693	,	_	_	
33-29	5694-5699	Calif	_	_	
33-30	5699-5700	.	_	_	

#Text=It is best that these sheets be connected (or grounded) to the outer conductor of the interconnecting applicator cable 16 shown in the Figures.
34-1	5701-5703	It	_	_	
34-2	5704-5706	is	_	_	
34-3	5707-5711	best	_	_	
34-4	5712-5716	that	_	_	
34-5	5717-5722	these	_	_	
34-6	5723-5729	sheets	_	_	
34-7	5730-5732	be	_	_	
34-8	5733-5742	connected	_	_	
34-9	5743-5744	(	_	_	
34-10	5744-5746	or	_	_	
34-11	5747-5755	grounded	_	_	
34-12	5755-5756	)	_	_	
34-13	5757-5759	to	_	_	
34-14	5760-5763	the	_	_	
34-15	5764-5769	outer	_	_	
34-16	5770-5779	conductor	_	_	
34-17	5780-5782	of	_	_	
34-18	5783-5786	the	_	_	
34-19	5787-5802	interconnecting	_	_	
34-20	5803-5813	applicator	_	_	
34-21	5814-5819	cable	_	_	
34-22	5820-5822	16	_	_	
34-23	5823-5828	shown	_	_	
34-24	5829-5831	in	_	_	
34-25	5832-5835	the	_	_	
34-26	5836-5843	Figures	_	_	
34-27	5843-5844	.	_	_	

#Text=Advantages of the present invention is the provision of a low cost, disposable applicator which is an integral part of a modified balloon type Foley catheter for the treatment of BPH.
35-1	5845-5855	Advantages	_	_	
35-2	5856-5858	of	_	_	
35-3	5859-5862	the	_	_	
35-4	5863-5870	present	_	_	
35-5	5871-5880	invention	_	_	
35-6	5881-5883	is	_	_	
35-7	5884-5887	the	_	_	
35-8	5888-5897	provision	_	_	
35-9	5898-5900	of	_	_	
35-10	5901-5902	a	_	_	
35-11	5903-5906	low	_	_	
35-12	5907-5911	cost	_	_	
35-13	5911-5912	,	_	_	
35-14	5913-5923	disposable	_	_	
35-15	5924-5934	applicator	_	_	
35-16	5935-5940	which	_	_	
35-17	5941-5943	is	_	_	
35-18	5944-5946	an	_	_	
35-19	5947-5955	integral	_	_	
35-20	5956-5960	part	_	_	
35-21	5961-5963	of	_	_	
35-22	5964-5965	a	_	_	
35-23	5966-5974	modified	_	_	
35-24	5975-5982	balloon	_	_	
35-25	5983-5987	type	_	_	
35-26	5988-5993	Foley	_	_	
35-27	5994-6002	catheter	_	_	
35-28	6003-6006	for	_	_	
35-29	6007-6010	the	_	_	
35-30	6011-6020	treatment	_	_	
35-31	6021-6023	of	_	_	
35-32	6024-6027	BPH	_	_	
35-33	6027-6028	.	_	_	

#Text=BPH is usually treated by surgery with significant side effects.
36-1	6029-6032	BPH	_	_	
36-2	6033-6035	is	_	_	
36-3	6036-6043	usually	_	_	
36-4	6044-6051	treated	_	_	
36-5	6052-6054	by	_	_	
36-6	6055-6062	surgery	_	_	
36-7	6063-6067	with	_	_	
36-8	6068-6079	significant	_	_	
36-9	6080-6084	side	_	_	
36-10	6085-6092	effects	_	_	
36-11	6092-6093	.	_	_	

#Text=These side effects include hemorrhage, impotency, anesthetic complications, and technical failures.
37-1	6094-6099	These	_	_	
37-2	6100-6104	side	_	_	
37-3	6105-6112	effects	_	_	
37-4	6113-6120	include	_	_	
37-5	6121-6131	hemorrhage	_	_	
37-6	6131-6132	,	_	_	
37-7	6133-6142	impotency	_	_	
37-8	6142-6143	,	_	_	
37-9	6144-6154	anesthetic	_	_	
37-10	6155-6168	complications	_	_	
37-11	6168-6169	,	_	_	
37-12	6170-6173	and	_	_	
37-13	6174-6183	technical	_	_	
37-14	6184-6192	failures	_	_	
37-15	6192-6193	.	_	_	

#Text=The use of the combined applicator catheter apparatus involves a treatment which requires no anesthesia or surgery and requires only 1 or 2 hour office visits to accomplish in comparison to post surgical hospitalization.
38-1	6194-6197	The	_	_	
38-2	6198-6201	use	_	_	
38-3	6202-6204	of	_	_	
38-4	6205-6208	the	_	_	
38-5	6209-6217	combined	_	_	
38-6	6218-6228	applicator	_	_	
38-7	6229-6237	catheter	_	_	
38-8	6238-6247	apparatus	_	_	
38-9	6248-6256	involves	_	_	
38-10	6257-6258	a	_	_	
38-11	6259-6268	treatment	_	_	
38-12	6269-6274	which	_	_	
38-13	6275-6283	requires	_	_	
38-14	6284-6286	no	_	_	
38-15	6287-6297	anesthesia	_	_	
38-16	6298-6300	or	_	_	
38-17	6301-6308	surgery	_	_	
38-18	6309-6312	and	_	_	
38-19	6313-6321	requires	_	_	
38-20	6322-6326	only	_	_	
38-21	6327-6328	1	_	_	
38-22	6329-6331	or	_	_	
38-23	6332-6333	2	_	_	
38-24	6334-6338	hour	_	_	
38-25	6339-6345	office	_	_	
38-26	6346-6352	visits	_	_	
38-27	6353-6355	to	_	_	
38-28	6356-6366	accomplish	_	_	
38-29	6367-6369	in	_	_	
38-30	6370-6380	comparison	_	_	
38-31	6381-6383	to	_	_	
38-32	6384-6388	post	_	_	
38-33	6389-6397	surgical	_	_	
38-34	6398-6413	hospitalization	_	_	
38-35	6413-6414	.	_	_	

#Text=The improvements of using the urethra cooling and the radiometric temperature measurement may enable a single treatment to be adequate to provide sufficient symptomatic relief as compared to the need of many treatments each a few days apart when the cooling is not used.
39-1	6415-6418	The	_	_	
39-2	6419-6431	improvements	_	_	
39-3	6432-6434	of	_	_	
39-4	6435-6440	using	_	_	
39-5	6441-6444	the	_	_	
39-6	6445-6452	urethra	_	_	
39-7	6453-6460	cooling	_	_	
39-8	6461-6464	and	_	_	
39-9	6465-6468	the	_	_	
39-10	6469-6480	radiometric	_	_	
39-11	6481-6492	temperature	_	_	
39-12	6493-6504	measurement	_	_	
39-13	6505-6508	may	_	_	
39-14	6509-6515	enable	_	_	
39-15	6516-6517	a	_	_	
39-16	6518-6524	single	_	_	
39-17	6525-6534	treatment	_	_	
39-18	6535-6537	to	_	_	
39-19	6538-6540	be	_	_	
39-20	6541-6549	adequate	_	_	
39-21	6550-6552	to	_	_	
39-22	6553-6560	provide	_	_	
39-23	6561-6571	sufficient	_	_	
39-24	6572-6583	symptomatic	_	_	
39-25	6584-6590	relief	_	_	
39-26	6591-6593	as	_	_	
39-27	6594-6602	compared	_	_	
39-28	6603-6605	to	_	_	
39-29	6606-6609	the	_	_	
39-30	6610-6614	need	_	_	
39-31	6615-6617	of	_	_	
39-32	6618-6622	many	_	_	
39-33	6623-6633	treatments	_	_	
39-34	6634-6638	each	_	_	
39-35	6639-6640	a	_	_	
39-36	6641-6644	few	_	_	
39-37	6645-6649	days	_	_	
39-38	6650-6655	apart	_	_	
39-39	6656-6660	when	_	_	
39-40	6661-6664	the	_	_	
39-41	6665-6672	cooling	_	_	
39-42	6673-6675	is	_	_	
39-43	6676-6679	not	_	_	
39-44	6680-6684	used	_	_	
39-45	6684-6685	.	_	_	
